title: Dose accuracy and injection force dynamics of a novel disposable insulin pen.
abstract: SoloStar (sanofi-aventis) is a new, disposable insulin pen for the administration of insulin glargine (Lantus, sanofi-aventis) or insulin glulisine (Apidra, sanofi-aventis). SoloStar was developed to address a wide range of patient needs and demonstrates advancement over previous devices, owing to its appropriate combination of ergonomically-tested and mechanically improved features. The authors report the results of key investigations carried out by sanofi-aventis as part of the SoloStar development plan, including dose accuracy and injection force testing. Comparisons between SoloStar and two commonly used pens, FlexPen (Novo Nordisk) and the Humulin/Humalog pen (Eli Lilly) establish SoloStar as a state of the art pen that is suitable for most patients with diabetes.
authors.affiliation: Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Site Frankfurt Devices/Device Design & Industrialisation, Industriepark Hoechst, Building K607, D-65926 Frankfurt am Main, Germany. Alastair.Clarke@sanofi-aventis.com
authors.forename: Alastair
authors.initials: A
authors.lastname: Clarke
authors.forename: Geralyn
authors.initials: G
authors.lastname: Spollett
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D016503:Drug Delivery Systems / Q000295:instrumentation; D004867:Equipment Design; D006804:Ergonomics; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007279:Injections, Subcutaneous / Q000295:instrumentation*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D019563:Mechanics
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine; C479079:insulin glulisine